drugset / Trial / NCT04226443

The Use of Midazolam and Remifentanil During Dialysis Access Procedures

NCT04226443 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC). OBJECTIVE: Our goal was to investigate and compare the sedation and analgesia related effects and adverse effects of continuous intravenous use of midazolam and intermittent bolus doses of midazolam while intravenous remifentanil is used as a rescue medication in patients with chronic renal failure.

Timeline

Start
2012-08-28
Primary completion
2016-04-15
Completion
2016-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midazolam Small molecule 0.015 mg/kg Intravenous
Comparator Midazolam Small molecule 0.02 mg/kg Intravenous
Comparator Midazolam Small molecule 0.04 mg/kg Intravenous
Comparator Remifentanil Small molecule 5 ug Intravenous
Comparator Remifentanil Small molecule 15 ug Intravenous